JOINN Laboratories (China) Co., Ltd. (HKEX: 06127) disclosed that on 16 March 2026 a group subsidiary subscribed to additional asset-management plans offered by CITIC Securities Co., Ltd. and its affiliates, lifting the aggregate outstanding principal of such investments to RMB460.00 million. The expanded exposure pushes the highest applicable percentage ratios under Chapter 14 of the Listing Rules above 5 % and below 25 %, rendering the transaction disclosable.
Breakdown of Outstanding Products • First to Sixth Products (signed Sept 2025–Dec 2025): combined principal RMB180.00 million, individual expected annualised returns ranging 1.5 %–5.15 %. • Seventh Product (signed 16 Mar 2026): principal RMB100.00 million, expected annualised return 2 %–5 %, maturity 23 Sep 2026. • Eighth Product (signed 16 Mar 2026): principal RMB180.00 million, expected annualised return 1.5 %–4.5 %, redeemable after 90 days.
Expected Interest Income Based on product-specific guidance, aggregate interest at maturity is projected between RMB5.97 million and RMB15.32 million, with individual product ranges reflecting differing tenors and rate bands.
Funding and Liquidity Impact JOINN financed the subscriptions with surplus cash. All products carry maturities of 12 months or less—or are open-ended with penalty-free redemption—providing management with flexibility for operational liquidity. The board states that no adverse impact on the group’s financial position is anticipated.
Strategic Rationale Management cites three factors for choosing the CITIC Securities products: 1. Relatively low risk profile versus other investment alternatives. 2. Higher indicative yields than standard PRC bank deposits. 3. Short-dated maturities that align with cash-management objectives.
Regulatory Context Prior to the March 2026 tranches, outstanding subscriptions remained below the 5 % threshold of Chapter 14. The two new investments lifted the aggregate to a level necessitating disclosure under Rule 14.34. Other CITIC Securities products reported on 14 April 2025 have been fully redeemed except for one remaining plan referenced in that announcement.
Counterparties CITIC Securities (Shanghai: 600030; HKEX: 6030) acts as product provider; China Capital Management Co., Ltd. and CITIC Securities Asset Management Co., Ltd. serve as related managers. Public information indicates all counterparties are independent of JOINN and its connected persons.
Company Profile JOINN is a PRC-based non-clinical contract research organisation expanding toward an integrated drug-R&D service platform encompassing discovery through clinical stages.